|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karam JA, Rini BI, Varella L, Garcia JA,
Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG,
et al: Metastasectomy after targeted therapy in patients with
advanced renal cell carcinoma. J Urol. 185:439–444. 2011.
View Article : Google Scholar
|
|
4
|
Paly JJ, Hallemeier CL, Biggs PJ,
Niemierko A, Roeder F, Martínez-Mong R, Whitson J, Calvo FA,
Fastner G, Sedlmayer F, et al: Outcomes in a multi-institutional
cohort of patients treated with intraoperative radiation therapy
for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol
Biol Phys. 88:618–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Richey SL, Tamboli P, Ng CS, Lin E, Lim
ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC and Tannir NM:
Phase II trial of pemetrexed plus gemcitabine in patients with
locally advanced and metastatic nonclear cell renal cell carcinoma.
Am J Clin Oncol. 36:450–454. 2013. View Article : Google Scholar
|
|
6
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
7
|
Milowsky MI and Nanus DM: Advanced renal
cell carcinoma. Curr Treat Options Oncol. 2:437–445. 2001.
View Article : Google Scholar
|
|
8
|
Blanco AI, Teh BS and Amato RJ: Role of
radiation therapy in the management of renal cell cancer. Cancers
(Basel). 3:4010–4023. 2011. View Article : Google Scholar
|
|
9
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katakami N, Atagi S, Goto K, Hida T, Horai
T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, et al:
LUX-Lung 4: a phase II trial of afatinib in patients with advanced
non-small-cell lung cancer who progressed during prior treatment
with erlotinib, gefitinib, or both. J Clin Oncol. 31:3335–3341.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smolle E, Taucher V, Petru E and Haybaeck
J: Targeted treatment of ovarian cancer–the multiple - kinase -
inhibitor sorafenib as a potential option. Anticancer Res.
34:1519–1530. 2014.PubMed/NCBI
|
|
12
|
Yang JC and Childs R: Immunotherapy for
renal cell cancer. J Clin Oncol. 24:5576–5583. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guenterberg KD, Lesinski GB, Mundy-Bosse
BL, Karpa VI, Jaime-Ramirez AC, Wei L and Carson WE III: Enhanced
anti-tumor activity of interferon-alpha in SOCS1-deficient mice is
mediated by CD4+ and CD8+ T-cells. Cancer
Immunol Immunother. 60:1281–1288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maeda S, Wada H, Naito Y, Nagano H,
Simmons S, Kagawa Y, Naito A, Kikuta J, Ishii T, Tomimaru Y, et al:
Interferon-α acts on the S/G2/M phases to induce apoptosis in the
G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell
line. J Biol Chem. 289:23786–23795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Lu J, He ML, i Z, Zhang B, Zhou LH,
Li Q, Li G, Wang L, Tian WD, et al: Antitumor effects of
interferon-alpha on cell growth and metastasis in human
nasopharyngeal carcinoma. Curr Cancer Drug Targets. 12:561–570.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motylewska E, Lawnicka H,
Kowalewicz-Kulbat M, Sicinska P, Niedziela A, Melen-Mucha G and
Stepien H: Interferon alpha and rapamycin inhibit the growth of
pheochromocytoma PC12 line in vitro. Endokrynol Pol. 64:368–374.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolf B, Schwarzer A, Côté AL, Hampton TH,
Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, et
al: Gene expression profile of peripheral blood lymphocytes from
renal cell carcinoma patients treated with IL-2, interferon-α and
dendritic cell vaccine. PloS One. 7:e502212012. View Article : Google Scholar
|
|
18
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A and Bex A:
EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol.
67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marigo I, Dolcetti L, Serafini P,
Zanovello P and Bronte V: Tumor-induced tolerance and immune
suppression by myeloid derived suppressor cells. Immunol Rev.
222:162–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diaz-Montero M, Finke J and Montero AJ:
Myeloid derived suppressor cells in cancer: Therapeutic,
predictive, and prognostic implications. Semin Oncol. 41:174–184.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao R, Li Q and Xiao B: Effect of Lycium
barbarum polysac-charide on the improvement of insulin resistance
in NIDDM rats. Yakugaku Zasshi. 125:981–988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li XM: Protective effect of Lycium
barbarum polysaccharides on streptozotocin-induced oxidative stress
in rats. Int J Biol Macromol. 40:461–465. 2007. View Article : Google Scholar
|
|
25
|
Chen Z, Kwong Huat Tan B and Chan SH:
Activation of T lymphocytes by polysaccharide-protein complex from
Lycium barbarum L. Int Immunopharmacol. 8:1663–1671. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gan L, Hua Zhang S, Liang Yang X and Bi Xu
H: Immunomodulation and antitumor activity by a
polysaccharide-protein complex from Lycium barbarum. Int
Immunopharmacol. 4:563–569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z, Lu J, Srinivasan N, Tan BK and
Chan SH: Polysaccharide-protein complex from Lycium barbarum L. is
a novel stimulus of dendritic cell immunogenicity. J Immunol.
182:3503–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miao Y, Xiao B, Jiang Z, Guo Y, Mao F,
Zhao J, Huang X and Guo J: Growth inhibition and cell-cycle arrest
of human gastric cancer cells by Lycium barbarum polysaccharide.
Med Oncol. 27:785–790. 2010. View Article : Google Scholar
|
|
29
|
Zhang M, Chen H, Huang J, Li Z, Zhu C and
Zhang S: Effect of Lycium barbarum polysaccharide on human hepatoma
QGY7703 cells: Inhibition of proliferation and induction of
apoptosis. Life Sci. 76:2115–2124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Booy S, van Eijck CH, Dogan F, van
Koetsveld PM and Hofland LJ: Influence of type–I Interferon
receptor expression level on the response to type-I Interferons in
human pancreatic cancer cells. J Cell Mol Med. 18:492–502. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shang D, Yang P, Liu Y, Song J, Zhang F
and Tian Y: Interferon-α induces G1 cell-cycle arrest in renal cell
carcinoma cells via activation of Jak-Stat signaling. Cancer
Invest. 29:347–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mao F, Xiao B, Jiang Z, Zhao J, Huang X
and Guo J: Anticancer effect of Lycium barbarum polysaccharides on
colon cancer cells involves G0/G1 phase arrest. Med Oncol.
28:121–126. 2011. View Article : Google Scholar
|
|
33
|
Markowitz J, Luedke EA, Grignol VP, Hade
EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV,
Lesinski GB, et al: A phase I trial of bortezomib and
interferon-alpha-2b in metastatic melanoma. J Immunother. 37:55–62.
2014. View Article : Google Scholar :
|
|
34
|
Zhu CP and Zhang SH: Lycium barbarum
polysaccharide inhibits the proliferation of HeLa cells by inducing
apoptosis. J Sci Food Agric. 93:149–156. 2013. View Article : Google Scholar
|
|
35
|
McIntosh GG, Anderson JJ, Milton I,
Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW and
Horne CH: Determination of the prognostic value of cyclin D1
overexpression in breast cancer. Oncogene. 11:885–891.
1995.PubMed/NCBI
|
|
36
|
Chen H, Tang L, Peng X, Luo Z, Luo S and
Tan W: Effects of IFN-alpha combined with IL-6 on cell growth and
related genes expression and apoptosis of bone marrow cells from
CGL patients. Zhonghua Xue Ye Xue Za Zhi. 21:341–344. 2000.In
Chinese.
|
|
37
|
Zitzmann K, Brand S, De Toni EN, Baehs S,
Göke B, Meinecke J, Spöttl G, Meyer HH and Auernhammer CJ: SOCS1
silencing enhances antitumor activity of type I IFNs by regulating
apoptosis in neuroendocrine tumor cells. Cancer Res. 67:5025–5032.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakashima A, Kumakura S, Mishima S,
Ishikura H and Kobayashi S: IFN-alpha enhances TNF-alpha-induced
apoptosis through downregulation of c-Myc protein expression in
HL-60 cells. J Exp Clin Cancer Res. 24:447–456. 2005.PubMed/NCBI
|
|
39
|
He YL, Ying Y, Xu YL, Su JF, Luo H and
Wang HF: Effects of Lycium barbarum polysaccharide on tumor
microenvironment T-lymphocyte subsets and dendritic cells in
H22-bearing mice. Chin Integr Med. 3:374–377. 2005.In Chinese.
View Article : Google Scholar
|
|
40
|
Luo Q, Li Z, Yan J, Zhu F, Xu RJ and Cai
YZ: Lycium barbarum polysaccharides induce apoptosis in human
prostate cancer cells and inhibits prostate cancer growth in a
xenograft mouse model of human prostate cancer. J Med Food.
12:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gan L, Wang J and Zhang S: Inhibition the
growth of human leukemia cells by Lycium barbarum polysaccharide. J
Hygiene Res. 30:333–335. 2001.In Chinese.
|
|
42
|
Gómez-Benito M, Balsas P, Carvajal-Vergara
X, Pandiella A, Anel A, Marzo I and Naval J: Mechanism of apoptosis
induced by IFN-alpha in human myeloma cells: Role of Jak1 and Bim
and potentiation by rapamycin. Cell Signal. 19:844–854. 2007.
View Article : Google Scholar
|
|
43
|
Christiansson L, Söderlund S, Svensson E,
Mustjoki S, Bengtsson M, Simonsson B, Olsson-Strömberg U and Loskog
AS: Increased level of myeloid-derived suppressor cells, programmed
death receptor ligand 1/programmed death receptor 1, and soluble
CD25 in Sokal high risk chronic myeloid leukemia. PLoS One.
8:e558182013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zoglmeier C, Bauer H, Nörenberg D,
Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S and
Bourquin C: CpG blocks immunosuppression by myeloid-derived
suppressor cells in tumor-bearing mice. Clin Cancer Res.
17:1765–1775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu J, Zhao LH and Chen Z: Stimulation by
Lycium bararum polysaccharides of the maturation of dendritic cells
in murine bone marrow. Zhejiang da xue xue bao. Journal of Zhejiang
University. Med Sci. 35:648–652. 2006.In Chinese.
|
